Quick Answer
LEMAITRE VASCULAR INC reported Research And Development Expense of $14.14 million for the year ending 2025.
- LEMAITRE VASCULAR INC showed a decrease of -9.7% in Research And Development Expense from 2024 to 2025.
- This data is from LEMAITRE VASCULAR INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $1.34 million | Q3 2010: $1.14 million | Q1 2011: $1.27 million | Q2 2011: $1.04 million | Q3 2011: $974.0 thousand | Q1 2012: $1.14 million | Q2 2012: $1.14 million | Q3 2012: $1.26 million | Q1 2013: $1.27 million | Q2 2013: $1.27 million | Q3 2013: $1.30 million | Q1 2014: $1.34 million | Q2 2014: $1.14 million | Q3 2014: $1.11 million | Q1 2015: $1.15 million | Q2 2015: $1.33 million | Q3 2015: $1.42 million | Q1 2016: $1.45 million | Q2 2016: $1.63 million | Q3 2016: $1.54 million | Q1 2017: $1.66 million | Q2 2017: $1.63 million | Q3 2017: $1.76 million | Q1 2018: $1.83 million | Q2 2018: $1.99 million | Q3 2018: $2.04 million | Q1 2019: $2.24 million | Q2 2019: $2.26 million | Q3 2019: $2.28 million | Q1 2020: $2.99 million | Q2 2020: $2.14 million | Q3 2020: $2.10 million | Q1 2021: $2.84 million | Q2 2021: $2.65 million | Q3 2021: $2.85 million | Q1 2022: $2.93 million | Q2 2022: $3.35 million | Q3 2022: $3.46 million | Q1 2023: $3.88 million | Q2 2023: $4.52 million | Q3 2023: $4.22 million | Q1 2024: $4.09 million | Q2 2024: $4.28 million | Q3 2024: $3.66 million | Q1 2025: $4.10 million | Q2 2025: $3.54 million | Q3 2025: $2.97 million.
- Over the full 17 years of available data (2009 to 2025), LEMAITRE VASCULAR INC's Research And Development Expense has grown by 139.2%.
- Historical annual values: Fiscal year 2025: $14.14 million | Fiscal year 2024: $15.65 million | Fiscal year 2023: $16.97 million | Fiscal year 2022: $13.29 million | Fiscal year 2021: $11.80 million | Fiscal year 2020: $10.10 million | Fiscal year 2019: $9.28 million | Fiscal year 2018: $8.20 million | Fiscal year 2017: $6.64 million | Fiscal year 2016: $6.14 million | Fiscal year 2015: $5.48 million | Fiscal year 2014: $4.67 million | Fiscal year 2013: $5.24 million | Fiscal year 2012: $5.09 million | Fiscal year 2011: $4.43 million | Fiscal year 2010: $5.49 million | Fiscal year 2009: $5.91 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: